Friday, July 10, 2026

pharma · Glioblastoma · Unresectable or metastatic soft tissue sarcoma

Philogen

Philogen clinical programs — 2 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Loc. Bellaria, 35, Sovicille, SIENA 53018, IT HQ
1996 Founded
180 Employees
EMA registrant Type
Company details
Status
Public
HQ
Loc. Bellaria, 35, Sovicille, SIENA 53018, IT
Founded
1996
Employees
180
Programs
18
Drugs
29
Patents
0
Intelligence · Clinical Programs

Philogen projects

2 ClinicalTrials.gov programs sponsored by Philogen.

Philogen has 2 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. Darleukin, Fibromun

    Philogen S.p.A.

    Malignant melanoma of the skin in patients with locally advanced and fully resectable melanoma with/without prior therapy and presence of injectable cutaneous and/or subcutaneous or nodal lesions

    phase 3 small molecule active

    1 trial
  2. PH-L19TNFDOX2-03/16

    Philogen S.p.A.

    Unresectable or metastatic soft tissue sarcoma

    phase 3 small molecule active

    1 trial

Frequently asked questions

How many clinical projects does Philogen have?

2 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.